Charles River Laboratories International (CRL) EBITDA Margin (2009 - 2025)

Charles River Laboratories International's EBITDA Margin history runs 17 years deep, the most recent figure standing at 28.51% for Q4 2025.

• In Q4 2025, EBITDA Margin fell 1178.0% year-over-year to 28.51%; the TTM figure through Dec 2025 stood at 0.63% (down 499.0% YoY), while the FY2025 annual figure was 0.63%, down 499.0% from the prior year.
• EBITDA Margin was 28.51% for Q4 2025 at Charles River Laboratories International, down from 13.32% in the prior quarter.
• In the past five years, EBITDA Margin ranged from a high of 19.26% in Q2 2022 to a low of 28.51% in Q4 2025.
• Historically, EBITDA Margin has averaged 10.81% across 5 years, with a median of 14.84% in 2022.
• The sharpest annual moves came in 2022 and 2024: EBITDA Margin jumped 422 bps in 2022, then tumbled 2984 bps in 2024.
• A 5-year view of EBITDA Margin shows it stood at 19.09% in 2021, then retreated by 22 bps to 14.89% in 2022, then slipped by 12 bps to 13.12% in 2023, then plunged by 228 bps to 16.73% in 2024, then tumbled by 70 bps to 28.51% in 2025.
• The last three EBITDA Margin figures came in at 28.51% (Q4 2025), 13.32% (Q3 2025), and 9.7% (Q2 2025), per Business Quant data.